Literature DB >> 2912775

Subclinical autoimmunity in recurrent aborters.

D B Maier1, A Parke.   

Abstract

Thirty-four women with habitual abortion (HA) were evaluated for the presence of lupus-associated autoantibodies, antisperm antibodies, and evidence of complement abnormalities. A control group of women who had only successful pregnancy outcomes also was studied. Fourteen HA women had anatomic, genetic, or hormonal causes for their pregnancy losses ("explained losses"), and 20 had no apparent causative factors ("unexplained losses"). Fifty percent of HA women with unexplained losses and 34% of women with explained losses had at least one abnormal result, but multiple autoimmune abnormalities were found only in women with unexplained losses. Anticardiolipin antibodies were found most commonly (30% of all HA women and 8% of controls). Two clinically normal HA women had multiple autoantibodies detected. This study suggests that recurrent pregnancy loss may be a marker for subclinical autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2912775

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  4 in total

1.  Lupus anticoagulants and anticardiolipin antibodies in Indian women with spontaneous, recurrent fetal loss.

Authors:  Akanksha Rawat; Meera Sikka; Usha Rusia; Kiran Guleria
Journal:  Indian J Hematol Blood Transfus       Date:  2014-07-08       Impact factor: 0.900

Review 2.  The role of IVIG in the management of patients with antiphospholipid antibodies and recurrent pregnancy losses.

Authors:  A Parke
Journal:  Clin Rev Allergy       Date:  1992 Spring-Summer

3.  Prevalence of antiphospholipid antibodies in patients with fetal loss.

Authors:  H J Out; H W Bruinse; G C Christiaens; M van Vliet; J F Meilof; P G de Groot; R J Smeenk; R H Derksen
Journal:  Ann Rheum Dis       Date:  1991-08       Impact factor: 19.103

4.  Pregnancy outcome in women with antiphospholipid antibodies.

Authors:  A K al-Momen; S A Moghraby; M O el-Rab; A M Gader; S R al-Balla; A A al-Meshari; L al-Nuaim
Journal:  Clin Rheumatol       Date:  1993-09       Impact factor: 2.980

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.